Use of Buserelin-Long FS in patients less than 60 years of age with locally advanced and generalized prostate cancer

Abstract

The paper gives the experience with Buserelin-long FS used to treat 17 patients aged 47 to 60 years with locally advanced and generalized prostate cancer. Analysis of the results of treatment following 2, 4, and 6 months has shown that the mean levels of testosterone and prostate-specific antigen reduced drastically after just 2 months. There is a simultaneous improvement in the quality of life.